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ABSTRACT: Introduction: The aim of this study was to test the
proficiency (accuracy among evaluators) of measured attributes
of nerve conduction (NC). Methods: Expert clinical neurophysi-
ologists, without instruction or consensus development, from 4
different medical centers, independently assessed 8 attributes
of NC in 24 patients with diabetes mellitus (DM) on consecutive
days. Results: No significant intraobserver differences between
days 1 and 2 were found, but significant interobserver differen-
ces were seen. Use of standard reference values did not cor-
rect for these observed differences. Conclusions: Interobserver
variability was attributed to differences in performance of NC. It
was of sufficient magnitude that it is of concern for the conduct
of therapeutic trials. To deal with interrater variability in thera-
peutic trials, the same electromyographers should perform all
NC assessments of individual patients or, preferably, NC proce-
dures should be more standardized. A further trial is needed to
test whether such standardization would eliminate interobserver
variability.
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Assessment of signs, symptoms, functional impair-
ments, and nerve tests are the the main clinical
measures used for diagnosing and characterizing
peripheral nerve disease. Among tests, nerve con-
duction (NC) has increasingly been advocated for
objective electrodiagnosis and characterization of
focal, multifocal, or generalized polyneuropa-
thies.1–4 NC is also being used for conducting epi-
demiological surveys5–7 and therapeutic trials.8,9
For the latter purposes, NC has gained consensus
approval,10–13 because its results are considered
sensitive, objective, quantitative, and reproducible
indications of nerve dysfunction that correlate with
clinical signs and symptoms and with neurophysio-
logical and neuropathological abnormalities.14,15
In knowing that assessment of attributes of NC
can provide sensitive and quantitative diagnostic
and characterizing information about diabetic sen-
sorimotor polyneuropathy (DSPN) for use in medi-
cal practice and therapeutic trials, it would also be
helpful to learn how accurately and reproducibly
within and among clinical neurophysiologists this
assessment is done (proficiency). There is already
considerable information about test–retest repro-
ducibility of individual attributes of NC focusing
mainly on which attributes show the greatest repro-
ducibility and, with this criterion, are suitable for
therapeutic trials (albeit test–retest reproducibility
is only 1 criterion for such selection). Reproduci-
bility studies have not addressed the issue of profi-
ciency—that is, the variability of NC results among
different clinical neurophysiologists without
retraining, consensus development, or quality con-
trol of their evaluations.
Two previous studies have assessed intra- and
interobserver variability of measured attributes of
NC. In the first study, electromyographers from 1
medical center studied healthy subjects,16 and in a
second they studied patients with diabetes mellitus
(DM).17 They found no significant intraobserver
differences, but significant interobserver differen-
ces. They concluded that, for therapeutic trials, it
may be advisable to have the same electromyogra-
phers perform the sequential NCs over time on
patients in the trial.
The present trial, Clinical vs. Neurophysiology
Trial 3 (Cl vs. NPhys Trial 3) had each group of
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clinical neurophysiologists and their associate tech-
nologist perform NC assessment of 8 attributes of
NC of the leg of 24 masked patients with DM with-
out and with DSPN on consecutive days. The
expert clinical neurophysiologists were asked to
make independent measurements of the attributes
without any clinical information, record whether
their values were normal or abnormal, and finally
make a judgment of whether the abnormalities
were diagnostic of DSPN. Thus, these studies spe-
cifically addressed 3 questions: (1) Did expert neu-
rophysiologists obtain the same measured values of
the 8 attributes of NC without intra- or interob-
server differences? (2) Assuming that they did, did
they judge abnormality of attributes without intra-
or interobserver differences? (3) Did they judge
DSPN as present or not without intra- or interob-
server differences? It was recognized prior to the
study that if the first question could not be
answered affirmatively, it may not be possible to
adequately assess questions (2) and (3). This trial
also addresses the broader question of whether fur-
ther standardization of NC assessment is needed
and possible, or whether it is really necessary to
have the same electromyographer perform serial
evaluations of individual patients.
This trial is part of a series of studies organized
by Cl vs. NPhys Trial investigators to assess the pro-
ficiency of assessment of signs, symptoms, and clin-
ical diagnosis,18,19 attributes of NC (the present
Trial 3) and other nerve tests for the diagnosis
and characterization of polyneuropathies, espe-
cially DSPN. The overall goal is to improve the
quality of these evaluations of measures of poly-
neuropathy in medical practice, medical educa-
tion, and the conduct of therapeutic trials.
METHODS
Study Setting and General Description. The trial was
performed in a small ballroom of the Kahler
Grand Hotel in Rochester, Minnesota, on Decem-
ber 8–9, 2011, after the study protocol and the
recruiting and consenting process had been
approved by the institutional review board of the
Mayo Clinic.
The original recruitment of subjects for Cl vs.
NPhys Trial 1 had focused on obtaining an even
number of patients without and with DSPN by NC
criteria. For the present trial, an attempt was made
to recruit the same group of patients, but 3 were
unable to participate, necessitating substitution of
other patients whose clinical and NC status (nor-
mal/abnormal) was not known until after comple-
tion of the study. Clinical neurophysiologists were
given information on age, gender, height, and
weight of the patients and were told that they
had DM, some without and others with DSPN.
Otherwise, their identity, disease status, and signs
and symptoms were withheld, and supervisory
attendants ensured complete blinding of patients’
identity and polyneuropathy status. Furthermore,
evaluators were told that all limbs to be examined
had been pre-warmed. Patients were asked not to
provide disease information, and examiners were
asked not to request such information. An hono-
rarium was paid to the research subjects to offset
their time away from other activities.
To carry out the examinations, we enlisted 4
expert clinical neurophysiologists and their associ-
ate technologist from Queen’s University, Kings-
ton, Ontario, Canada (C.B. and N.W.); the
University of Maryland, Baltimore, Maryland (J.R.
and K.T.); the University of Michigan, Ann Arbor,
Michigan (J.A. and J.W.); and the Mayo Clinic,
Rochester, Minnesota (C.K. and A.Z.). The clinical
neurophysiologist and technologist both partici-
pated in nerve conduction assessment. There was
no training or consensus development before the
trial. The evaluators independently performed NC
tests using different electromyographic (EMG)
instruments, test peripherals, and their own proce-
dures. They were asked not to confer with each
other about test procedures or the normal values
to be used. However, these clinical neurophysiolo-
gists were all asked to evaluate the same 8 attrib-
utes of NC of the left leg of the same masked 24
patients on 2 consecutive days. The 4 groups of
evaluators were stationed in 4 curtained cubicles at
the periphery of the hotel ballroom so that lower
limbs from patients lying on examining beds could
be introduced for their NC assessment without
examiners seeing the patients’ upper bodies (Fig.
1). This physical arrangement also allowed study
personnel to readily rotate (every 15–20 minutes)
patients among the different clinical neurophysiol-
ogists, and it prevented recognition of patients by
their physical appearance. Moreover, random
assignment of patients to test cubicles was used to
prevent recognition of patients by order of their
evaluation. Each testing cubicle was equipped with
separate (and, in some cases, different) manufac-
turers’ EMG instruments, along with individual
stimulation and recording electrodes, tape to hold
electrodes in place, grease pencils to mark test
sites, and measuring tapes. Study coordinators had
warmed the left leg of patients by immersion in
hot water prior to the onset of testing; heat lamps
were used to maintain limb temperature; and,
between tests, limbs were kept warm (31–34C) by
use of applied insulating leg casts. After comple-
tion of NC testing and before transfer of the
patients to a different cubicle, all indicators of
electrode placement or sites of stimulation were
removed by supervisory personnel.
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After performing the NC assessments, the clini-
cal neurophysiologists calculated NC values and
completed forms indicating whether measured
individual attributes were normal or abnormal and
then made a judgment of whether patients had
electrodiagnostic evidence of DSPN. Examiners
provided measurements of fibular nerve amplitude
[compound muscle action potential (CMAP)];
motor nerve conduction velocity (MNCV), and
motor nerve distal latency (MNDL); tibial CMAP,
MNCV, and MNDL; and sural sensory nerve action
amplitude (SNAP) and sensory nerve distal latency
(SNDL). Immediately after the study of each
patient, the data forms and the machine tracings
were collected by study coordinators.
Analysis. Standard descriptive statistical tests were
used to assess intra- and interrater agreement of
measured attributes of NC, judgment of attribute
abnormality, and diagnosis of DSPN. The analyses
and statistical tests used are described from point
of use in the Results section. To assess whether use
of standard reference values could improve profi-
ciency, we also converted measured NC attribute
values to percentiles using standard reference
values obtained in a previously studied healthy sub-
ject cohort of 330 subjects (from an initially eval-
uated group of 430 Olmsted County, Minnesota,
USA residents), without metabolic or neurological
disease and who were normal by neurological ex-
amination and laboratory tests, such as fasting
plasma glucose, plasma creatinine, and percent
plasma hemoglobin A1c, and the Rochester Dia-
betic Neuropathy Study healthy subject cohort
(RDNS-HS).20,21 These percentile reference values
of measured attributes of NC were corrected as ap-
plicable for the influence of age, gender, height,
weight, body mass index, and body surface area.
Abnormality of an attribute of NC was set at
2.5th or 97.5th percentile. For a comparative
standard and referenced criterion for DSPN, we
used R5 NC nds (standard normal deviates of fibu-
lar CMAP, MNCV, and MNDL; tibial MNDL; and
sural SNAP).22,23 To derive this composite score,
the average value of measurable attributes was mul-
tiplied by 5 (with all attributes placed into the
lower tail of the normal distribution). The 2.5th
percentile line of this composite score was set
using the RDNS-HS data just described.
RESULTS
Raw Values and Intra- and Interrater Agreement of
Measured Attributes of NC. The variability of raw
values of attributes of NC as measured among the
evaluators is shown in Table S1 (see online Supple-
mentary Material). The median and range values
overlapped in all cases, but differences of some
magnitude occurred in some instances. Using coef-
ficients of variation, the differences of measured
values on days 1 and 2, respectively, were as fol-
lows: fibular CMAP, 90.2% and 92.9%; fibular
MNCV, 16.2% and 14.2%; fibular MNDL, 18.4%
and 20.2%; tibial CMAP, 99.3% and 97.5%; tibial
MNCV, 14.1% and 14.0%; tibial MNDL, 20.2% and
23.2%; sural SNAP, 92.4% and 90.6%; and sural
SNDL, 11.2% and 12.0%. Clearly, motor NC veloc-
ities and distal latency were much less variable
than were motor or sensory amplitudes (findings
from earlier studies).
No statistically significant intraobserver differ-
ences were found for the 4 clinical neurophysiolo-
gists’ assessments of measurement of attributes of
NC between days 1 and 2 (Table S1). By contrast,
significant interobserver differences were observed
for 8 of 8 attributes on day 1 and for 7 of 8
attributes on day 2 (shown as bold entries in Table 1);
the only exception on day 2 was fibular MNCV.
Intra- and Interobserver Agreement of Judgment of
Abnormality of Attributes of NC. Using the kappa-
coefficient, highly significant intraobserver agree-
ment between days 1 and 2 was observed for the 4
clinical neurophysiologists’ judgments of abnormal-
ity of all attributes of NC, with the exception of the
group 3 assessment of fibular MNDL (Table S2).
By contrast, statistically significant interobserver
differences in judgment of abnormality of attrib-
utes of NC were observed 6 of 16 times (shown as
bold entries in Table 2); that is, tibial CMAP and
sural SNAP, each 2 times, and tibial MNCV and
sural SNDL, 1 time. However, in addition, nearly
FIGURE 1. The physical arrangement used to assess attributes
of nerve conduction in the Cl vs. NPhys Trial 3, allowing
masked examination of 24 patients with diabetes on 2 separate
days. Curtained examination cubicles for NC assessment were
at the periphery of the ballroom, which permitted lower limbs of
the patients to be introduced for examination without the exam-
iners being able to identify patients by their physical appear-
ance. This setup allowed examiners to explain what was being
done to each patient. It also allowed patients to report on ex-
cessive symptoms or reactions to the tests being given while
not revealing their identity or disease condition.
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significant differences (P  0.1) were observed for
3 other attributes (Table 2).
Intraobserver Agreement of Diagnosis Based on
“Evaluators’ Judgment” vs. “Standard Reference Val-
ues” (i.e., R5 NC nds £2.5th percentile) from RDNS-
HS. As shown in Table S3, we tested for differ-
ence of clinical physiologists’ “judgment of
abnormality” as compared with “referenced
abnormality”; that is, 2.5th and 97.5th percen-
tile, based on RDNS-HS data. Regardless of which
attribute was evaluated, a significant difference was
not observed between days 1 and 2. By contrast,
strikingly significant differences were found
between “judged” and “referenced” abnormality
(significant values shown as shaded boxes in last 2
columns). For fibular CMAP, “judged” was more
frequently abnormal than was “referenced” abnor-
mality, whereas, for fibular and tibial MNCV and
sural SNAP and SNDL, the converse was found—
“referenced” was more frequently abnormal than
was “judged.” Other attributes were much more
inconsistent, such as tibial CMAP.
Intraobserver Agreement of Clinical Neurophysiolo-
gists’ “Judged” vs. “Referenced” Electrodiagnosis of
DSPN. Whereas no intraobserver difference was
observed between days 1 and 2, significant differ-
ences between “judged” and “referenced” diagnosis
were observed for 7 of 8 comparisons (shaded area
in Table S4).
DISCUSSION
Accurate assessment of the diagnosis and sever-
ity of polyneuropathies such as DSPN is needed
for quality medical practice, epidemiological sur-
veys, and the conduct of therapeutic trials. Profi-
ciency (accuracy among evaluators) of such
assessments has not been emphasized sufficiently
in the past, perhaps due to the assumption that
clinical evaluations are expertly and proficiently
done, especially among professionals who have
received specialty training and certification. How-
ever, when actually tested, clinical proficiency was
not as good as expected. Prototypical studies of
intra- and interexaminer reliability (reproducibil-
ity) of measured attributes of NC were performed
by Chaudhry et al. in healthy subjects16 and in
patients with diabetic neuropathy.17 In their first
study, 7 experienced electromyographers assessed
NCs of 4 other members of their group on 2 occa-
sions. In their second study, 6 experienced electro-
myographers performed duplicate NC studies on 6
patients with polyneuropathy. In both studies,
intraexaminer agreement was high, but significant
interobserver differences were found, indicating
Table 1. Significant interobserver differences (bold) of measured
attributes of nerve conduction in Cl vs. NPhys Trial 3.*
Friedman v2 test for differences
among 4 Cl vs. NPhys teams
Day 1 Day 2
Nerve conduction attribute v2 P v2 P
Fibular CMAP (mV) 22.06 <0.01 33.10 <0.01
Fibular MNCV (m/s) 9.97 0.02 1.17 0.76
Fibular MNDL (ms) 28.43 <0.01 36.55 <0.01
Tibial CMAP (mV) 40.55 <0.01 32.03 <0.01
Tibial MNCV (m/s) 21.70 <0.01 12.95 <0.01
Tibial MNDL (ms) 20.15 <0.01 39.14 <0.01
Sural SNAP (lV) 15.00 <0.01 15.20 <0.01
Sural SNDL (ms) 15.16 <0.01 24.45 <0.01
A full table showing the raw values of clinical neurophysiologists’ meas-
urements and intraobserver agreement of measured attributes of nerve
conduction is shown in Table S1 (see online Supplementary Material).
*No significant intraobserver differences were observed between days 1
and 2 for any group of electromyographers.
Table 2. Significant interobserver differences (bold) of clinical neurophysiologist judgment of abnormality of attributes of nerve conduction
in the Cl vs. NPhys Trial 3.*
Nerve conduction attribute
Cochran’s Q-test for differences among 4 Cl vs. NPhys Trial 3 teams
Day 1 Day 2
Q P Q P
Fibular CMAP abnormal (doctor’s judgment) 6.60 0.09 3.00 0.39
Fibular MNCV abnormal (doctor’s judgment) 6.14 0.10 4.00 0.26
Fibular MNDL abnormal (doctor’s judgment) 3.00 0.39 6.00 0.11
Tibial CMAP abnormal (doctor’s judgment) 13.86 <0.01 10.50 0.01
Tibial MNCV abnormal (doctor’s judgment) 9.58 0.02 3.38 0.34
Tibial MNDL abnormal (doctor’s judgment) 6.00 0.11 5.53 0.14
Sural SNAP abnormal (doctor’s judgment) 11.90 <0.01 19.91 <0.01
Sural SNDL abnormal (doctor’s judgment) 6.43 0.09 15.89 <0.01
Intraobserver clinical neurophysiologist agreement of judgment of abnormality of attributes of nerve conduction is shown in Table S2 (online Supplementary
Material).
*Significant intraobserver differences were not observed between days 1 and 2 for any group of electromyographers, with 1 exception (i.e., electromyogra-
pher no. 3 for fibular MNDL).
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differences in performance of NC assessments.
Chaudhry and colleagues concluded that, “…if NC
studies are to be used longitudinally (i.e., for ther-
apeutic trials) they should optimally be performed
by a single examiner to minimize the degree of
variability associated with different examiners.”
Additional reports focused on test–retest reprodu-
cibility of and among evaluations of different
attributes of NC,24–29 but these studies differ from
Chaudhry et al. and our study by not comparing
NC as is usually done in medical practice. These
latter studies often provided specific directions on
how to perform NC and offered a degree of quality
control of the NC examination. Also, in most of
the latter studies, differences among clinical neu-
rophysiologists were not assessed. Instead, the
focus was on which attribute showed the lowest
test–retest reliability.4,23,24,26,29
From a review of medical publications, there is
ample evidence that the methods used to test and
stage severity of DSPN are not as proficient as
intended.30 Lack of clinical proficiency of the assess-
ment of signs and symptoms of polyneuropathy was
demonstrated unequivocally in the Cl vs. NPhys Trial
1. In that study, the investigators markedly over-
reported signs and, to a lesser degree, DSPN
symptoms and diagnosis, presumably emphasizing
sensitivity over specificity.18 When they became aware
of their overreporting, and the trial was repeated
using “only unequivocal abnormality” (taking age,
gender, physical fitness, and physical variables into
account) as a criterion for abnormality, their clinical
proficiency improved dramatically.19 The trial investi-
gators suggested that, for medical practice, epidemio-
logical surveys, and therapeutic trials, the more
specific criteria should be used.
The present trial (Cl vs. NPhys Trial 3) has
focused on proficiency of NC assessment of 4 inde-
pendent expert clinical neurophysiologists and
associated technologists drawn from different med-
ical centers in North America. It extends the Johns
Hopkins studies by: (1) study of a larger number
of patients, specifically 24 patients; (2) involving
clinical neurophysiologists and their technologists
from 4 widely distributed North American medical
schools; (3) employing different EMG instruments
and stimulating and recording peripherals; and
(4) assessing judgment of abnormality of individ-
ual attributes and of the diagnosis of DSPN.
We found that, although intraobserver variabili-
ty was not significantly different, interobserver vari-
ability was significantly different for many NC
attributes and for the judgments of abnormality.
We judge interrater variability to be excessive,
especially for the conduct of therapeutic trials.
Using the raw values (median and range), one
observes that measured attributes of NC were
similar and overlapping among the 4 clinical neu-
rophysiologists, suggesting that these measured val-
ues are sufficiently accurate for use in the
identification and characterization of DSPN in
medical practice. However, when variability was
expressed as coefficient of variation, quite large
differences among the NC attributes were
observed, and this variability was greater for some
attributes (motor and sensory amplitude) than for
others (conduction velocity and distal latency).
Because amplitude measurements probably relate
more closely to clinical deficit, their excessive
interobserver variability is of concern, especially
for the conduct of therapeutic trials. This signifi-
cant interobserver variability extended to judgment
of attribute abnormality and to a lesser degree to
electrodiagnosis of DSPN—that is, it was not statis-
tically significant for day 1, but it was significant
(P50.05) for day 2.
What is the likely explanation for the interob-
server variability of measured attributes of NC? By
nature of the design of these studies, the differen-
ces cannot be explained readily by physiological
alterations of nerves, because only inter- and not
intraobserver differences were observed, whereas
measurements underlying intra- and interobserver
differences were performed concurrently. Also, the
interobserver difference cannot be due to the
superior or inferior performances of individual
clinical neurophysiologists, because results of all
groups were overlapping. Therefore, we conclude,
as did Chaudhry et al.,20,21 that the variation must
relate to differences in test performance; that is,
testing is still not standardized sufficiently.
Is the interobserver variability we found clini-
cally meaningful such that improvement is
needed? The answer probably depends on what
use is to be made of the results. Some degree of
variability may be acceptable for some purposes;
however, for therapeutic trials it is not acceptable
to have the degree of interobserver variability as
reported here. The observed differences are suffi-
ciently large to be of concern, especially for thera-
peutic trials in which small differences between
treatments (treatment and sham) can markedly
affect the power of the trial.
How can proficiency be improved? As suggested
by Chaudhry et al.,20,21 the same clinical neuro-
physiologists could be asked to do all serial evalua-
tions of individual patients. A second approach
would be to standardize and optimize the perform-
ance of NC so that interobserver differences would
be eliminated. For conduct of therapeutic trials,
preliminary training sessions and quality control of
examinations are probably needed. We believe
that, with sufficient standardization and training,
interobserver variability can be eliminated. To test
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this possibility a further trial has been planned.
Finally, it is evident that use of high-quality refer-
ence values, although meritorious, cannot take the
place of accurate and highly standardized NC
measurements.
APPENDIX
Additional Cl vs. NPhys Trial 3 investigators: P. James
B. Dyck, MD, Phillip A. Low, MD, and Carol J.
Overland, MD (all from Department of Neurology,
Mayo Clinic, Rochester, MN; additional members of
the coordinating committee); Henning Andersen,
MD (Aarhus University Hospital, Aarhus, Den-
mark); John D. England, MD (Department of Neu-
rology, Louisiana State University, New Orleans,
LA); Gareth Llewelyn, MD (University Hospital of
Wales, Cardiff, Wales, UK); Michelle L. Mauer-
mann, MD (Department of Neurology, Mayo Clinic,
Rochester, MN); Dinesh Selvarajah, MD (Royal Hal-
lamshire Hospital, Sheffield, UK); Wolfgang Singer,
MD (Department of Neurology, Mayo Clinic, Roch-
ester, MN); A. Gordon Smith, MD (University of
Utah, Salt Lake City, UT); and Solomon Tesfaye,
MD, and Adrian Vella, MD (Division of Endocrinol-
ogy, Diabetes, Metabolism and Nutrition, Mayo
Clinic, Rochester, MN; study neurologists and
diabetologists).
The authors are grateful for the help of JaNean K. Engelstad and
Lawrence V. Witt (Peripheral Neuropathy Research Laboratory);
Sarah A. Motl, Sherry K. Moyer, and Kay A. Spavin (EMG Labora-
tory); Jennifer A. Winkler, BS, and Karen A. Lodermeier (QST
Laboratory); and Randall C. Newman, BSEE, and Shaun Herring
(Section of Engineering). Mary Lou Hunziker prepared the manu-
script. These studies could not have been done without the dedi-
cated and expert help from patients in the Rochester Diabetic
Neuropathy Study.
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